Monitoring of ischemia with OnZurf Probe is accepted for scientific publication

The first scientific publication with OnZurf probe "Surface microdialysis on small bowel serosa the monitoring of ischemia" is accepted for publication in the Journal of Surgical Research.

The study shows that samples collected with OnZurf Probe from the surface of the small bowel indicated the lack of oxygen already after 20 minutes. No other parameters or samples indicated early signs of reduced oxygen supply.

The article is available online.

http://www.journalofsurgicalresearch.com/article/S0022-4804(16)30010-5/abstract

For further information, please contact:

Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

Pernilla Abrahamsson, Product and business development manager Senzime AB

Tel: +46 70-37 37 472, e-post: pernilla.abrahamsson@senzime.com

TO THE EDITORS

About Senzime

Senzime develops patient-oriented systems enabling automated and continuous monitoring of vital substances such as glucose and lactate in blood and tissue. Based on Senzime's patented biosensor technology, the company offers complete patient monitoring systems for the health care market. Senzime's products consist of the CliniSenz Analyzer and OnZurf Probe that make it possible, among other things, to detect post-operative complications significantly earlier than by conventional methods, thus contributing to improved patient care and lower health care costs. The company's share is listed on Aktietorget, Stockholm. www.senzime.com

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com

Subscribe

Documents & Links